 Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of PovertyMonograph from Office of Health Economics Abstract: Improving the health and life expectancy of the populations of the less developed countries of the world requires both better access to medicines and research and development (R&D) of new drugs, vaccines and diagnostics. Achieving the latter is a critical part of a package of steps needed to treat and ultimately eradicate the infectious diseases prevalent predominately in the poorest regions of the developing world. This book focuses on the role of public-private partnerships (PPPs) as an innovative approach to the discovery, development and provision of drugs and vaccines for less developed countries. It considers the challenges such PPPs will face if they are to be successful, using four case studies. These are: ● the Medicines for Malaria Venture (MMV); ● the International AIDS Vaccine Initiative (IAVI); ● the Malaria Vaccine Initiative (MVI); and ● the Global Alliance for TB Drug Development (GATB). All four focus on the top three infectious disease killers in the developing world: malaria, TB, and HIV/AIDS. Keywords: Public; Private; Partnerships; for; Research; and; Development:; Medicines; and; Vaccines; for; Diseases; of; Poverty (search for similar items in EconPapers) Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:ohe:monogr:000479 Access Statistics for this paper More papers in Monograph from Office of Health Economics Contact information at EDIRC. |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.